Our commitment to Research and Development has resulted in the development of innovative technologies and a strong portfolio of patents. We are pleased to offer our technologies for licensing and commercial use through our out-licensing program in the fields of Nucleic Acid-Based Therapy, Molecular Biology and Diagnostics.

Currently, out-licensing agreements are available for the following technologies:

  • Zip Nucleic Acids (ZNA®)

Besides, Polyplus-transfection® is open to discuss any other licensing/collaboration opportunities for our products or technologies, as well as potential partnerships that may be of mutual interest.

Contact Us


Key-words: Gene therapy, short interfering RNAs, siRNA delivery, gene silencing, preclinical study, cancer therapy, in vivo-jetPEI®

STICKY SIRNAs are a new class of short interfering RNAs designed to dramatically improve in vivo siRNA delivery and activity. STICKY SIRNAs display increased siRNA and formulation stability with in vivo -jetPEI®, improved gene silencing efficiency and do not induce pro-inflammatory cytokine responses.  Internal research efforts have provided preclinical proof of concept for STICKY SIRNA for in vivo delivery of therapeutic oligonucleotides in many cancer and metastasis models. Many STICKY SIRNAs inhibiting tumor cell growth or inducing apoptosis have been validated. In addition, this technology can be combined with chemotherapy treatments. Results of preclinical efficacy data and safety studies in mice for lung metastatic cancer, melanoma xenograft and prostate cancer are available on demand.

We are interested in building relationships for partnering or out-licensing STICKY SIRNAs for the clinical development of our technology. We are flexible and open to many forms of relationships.

Learn more about STICKY SIRNA.

Intellectual Property: STICKY SIRNAs are the subject matter of US Patent No. 8,802,640, US divisional patent application no. 14/321086, European Patent No. 1 888 749 and foreign equivalents entitled “Oligonucleotides for RNA interference and biological applications thereof”.


Key-words: nucleic-acid based therapy, therapeutic siRNAs, antisense, self-delivering oligonucleotides, cancer therapy, brain neuronal Stem Cells

OLIGOPLUS are a new class of self-delivering cationic modified oligonucleotides that require no delivery agent. This technology can apply to different classes of therapeutic oligonucleotides such as siRNA, antisense and anti-miR. In the case of siRNA, a sub-class called SIRNAPLUS™ has been developed and fully characterized. SIRNAPLUS® has been demonstrated as an innovative and highly effective technology for the intracellular self-delivery of siRNAs. The in vivo efficacy of SIRNAPLUS® is currently under review in a study of gene silencing activity in neuronal progenitor cells in mouse brain, in xenograph tumor and in lung metastasis models. Recent investigations have also shown that OLIGOPLUS can serve as effective antisense and antigen agents.

We are actively seeking partners to license OLIGOPLUS and SIRNAPLUS® for a wide range of indications and applications.


Intellectual Property: OLIGOPLUS and Spermine Phosphoramidite are the subject matter of U.S. Patent No. 9090648, European Patent No. 1 973 927 and foreign equivalents entitled “Cationic oligonucleotides, automated methods for preparing same and their uses”. SIRNAPLUS® are the subject matter of Patent Application WO/2009/095887 entitled “Cationic siRNAs, synthesis and use for RNA interference”.

Zip Nucleic Acids (ZNA®)

Key-words: Zip Nucleic Acids (ZNA®), Spermine phosphoramidite, Molecular Biology, Molecular Diagnostics, PCR, RT-PCR, primers, probes, miRNA detection, multiplex assays, SNP discrimination, In Situ Hybridization (ISH)

Polyplus-transfection® is seeking to license synthesis and commercialization of Zip Nucleic Acids (ZNA®) molecules to oligonucleotide manufacturers. In addition, Polyplus-transfection is looking for partners who wish to develop assays and applications using ZNA® oligonucleotides in Molecular Biology and Molecular Diagnostics, including IVD Kits.

The purchase of ZNA® oligonucleotides or Spermine Phosphoramidite does not include or carry an implied right or license for the buyer to use such products for commercial purposes. A license must be obtained directly from Polyplus-transfection for commercial use of these products, including but not limited to use in diagnostic procedures. For a commercial license to the ZNA® Intellectual Property, please contact us.

Learn more about ZNA®.

Intellectual Property: ZNA® oligonucleotides, Spermine phosphoramidite and their use are the subject matter of (i) U.S. Patent No. 9090648, U.S. Divisional Patent Application No. 14/745,871, European Patent No. 1 973 927 and foreign equivalents entitled “Cationic oligonucleotides, automated methods for preparing same and their uses” and (ii) U.S. Patent No. 8,465,920, European Patent No. 2 225 393 and foreign equivalents entitled “Methods for hybridizing nucleic acids”.


It is reminded that FectoVIR®-AAV transfection reagent is claimed under the patent portfolio issuing and deriving from the priority European patent application filed in the name of Polyplus-transfection S.A. (hereinafter referred to as the “Patents”).
It shall be the responsibility of customer to ensure that:

  • all and any of his use of FectoVIR®-AAV transfection reagent does not infringe any intellectual property right of third party and, if necessary, that it has been granted by the corresponding third party all the necessary exploitation rights, Polyplus-transfection SA disclaiming any responsibilities on this subject, and that
  • the implementation of any of the intellectual property right which might be filed by customer from the priority date of the Patents, in relation with FectoVIR®-AAV transfection reagent, does not require any rights under the Patents, in compliance with all and any applicable Intellectual Property Laws